• ImpediMed surges as the US NCCN included bioimpedance spectroscopy (BIS) as part new guidelines
  • ImpediMed has the only FDA-cleared BIS technology for the assessment of lymphoedema
  • GTG adds 3 new diseases to its geneType Multi-Test


ImpediMed (ASX:IPD) surged over 60% this morning after announcing that the US National Comprehensive Cancer Network (NCCN) has included bioimpedance spectroscopy (BIS) as part of its new guidelines.

The new NCCN Guidelines specifically named bioimpedance spectroscopy (BIS) as an objective measurement tool to identify early signs of lymphoedema.

It has also recommended regular screening for all cancer survivors at risk of lymphoedema, in addition to identifying early signs of lymphoedema via symptom assessment, clinical exam, and, if available, bioimpedance spectroscopy.

The inclusion of BIS in the NCCN Guidelines will now help establish BIS as standard of care, and will accelerate adoption by US private payors and providers.

“The recommendation in the NCCN Guidelines for the use of bioimpedance spectroscopy technology is a major validating moment for the company,” said Richard Valencia, CEO of ImpediMed.


The only FDA-cleared BIS technology

ImpediMed currently has the only FDA-cleared BIS technology for the assessment of lymphoedema. The company’s SOZO Digital Health Platform is broadly accepted and recognised for effective and accurate screening of lymphoedema.

The NCCN meanwhile is a non-profit alliance of leading cancer centres in the US, and its Guidelines are the globally recognised standard for clinical direction and policy in cancer care.

Most large private insurance companies use recommendations from the NCCN Guidelines as the basis for coverage policy determinations.

“The authors of the NCCN Guidelines are world leaders in global cancer care, driven by sound clinical evidence and patients’ best interests,” said Valencia.

“Their recommendations are highly influential for clinicians, patients, policymakers, and insurance companies.”

The new recommendations include two references to BIS technology in the sections called SLYMPH-2 and SLYMPH-3.

SLYMPH-2 lists the principles of lymphoedema, while SLYMPH-3 outlines an algorithm for assessing and treating survivors at risk of lymphoedema.

“We will take the information in these updated NCCN Guidelines and immediately integrate it into our reimbursement strategy to expand coverage of SOZO testing for lymphoedema,” said Valencia.

“Longer-term, these guidelines also support an opportunity to expand into other cancer types, broaden our footprint in oncology, and benefit even more patients,” he added.


ImpediMed share price today:


GTG adds 3 new diseases to geneType Multi-Test

Genetic Technologies (ASX:GTG) has announced the initiation of Phase 2 rollout plan for its geneType Multi-Test.

The expanded panel now includes three new diseases, taking the total number of individual risk assessments included in the geneType Multi-Test to nine – all from the one simple saliva sample.

The new diseases to be included in the test are: Melanoma, Pancreatic Cancer, and Atrial Fibrillation – broadening the utility of Impedimed’s geneType Multi-Test.

Data shows that each of the three diseases cause significant mortality and morbidity.

According to the American Cancer Society, there will be approximately 97,610 new cases of melanoma in 2023, and 7,990 people are expected to die from the disease.

Pancreatic cancer is even more dramatic with 64,050 people newly diagnosed in 2023, with a staggering 50,550 people expected to die.

In the case of atrial fibrillation (AFib), the Centers for Disease Control (CDC) noted that in 2022 there were more than 454,000 hospitalisations, and approximately 158,000 deaths each year in the US.

“The company continues to deliver on our commitment to being a world leader in delivering personalised risk assessments to enable preventative healthcare for a range of serious diseases,” said GTG’s CEO, Simon Morriss.


GTG share price today: